ABMD

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Abiomed Inc.

Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
CEO
Michael Minogue
Employees
1725
Headquarters

22 Cherry Hill Dr
Danvers, Massachusetts 01923-2575
Phone: 19787775410
www.abiomed.com

News

Abiomed: Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
Aug 16, 2022 12:15pm

Consistent evidence supports benefits of complete revascularization on LVEF, heart failure symptoms Abiomed (Nasdaq: ABMD) announces the results of the Restore EF study demonstrate Impella-support…


Source:Finanz Nachrichten
Why Shares of Abiomed Rose 18.4% in July
Aug 08, 2022 19:21pm

The company''s stock rose steadily throughout the month.


Source:The Motley Fool
ABIOMED, Inc. (ABMD) Q1 2023 Earnings Call Transcript
Aug 05, 2022 12:13pm

ABIOMED, Inc. (NASDAQ: ABMD) Q1 2023 earnings call dated Aug. 04, 2022 Corporate Participants: Nicole Nath — Manager of Investor Relations Michael R. Minogue — Chairman, Chief Executive Officer and President Todd A. Trapp — Executive […] The post ABIOMED, Inc. (ABMD) Q1 2023 Earnings Call Transcript first appeared on AlphaStreet .


Source:AlphaStreet
ABIOMED, Inc. (ABMD) Q1 2023 Earnings Call Transcript | AlphaStreet
Aug 05, 2022 12:13pm

ABIOMED, Inc. (NASDAQ: ABMD) Q1 2023 earnings call dated Aug. 04, 2022


Source:AlphaStreet
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2023 Results - Earnings Call Transcript
Aug 04, 2022 18:55pm

Abiomed, Inc. (NASDAQ:NASDAQ:ABMD) Q1 2023 Results Conference Call August 4, 2022 08:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and…


Source:Seeking Alpha
Abiomed shares fall as med tech lowers 2022 revenue guidance (NASDAQ:ABMD)
Aug 04, 2022 18:31pm

Abiomed (ABMD) is down 4% in Thursday afternoon trading after the medical technology company lowered its full-year revenue guidance due to impacts from foreign exchange rates.


Source:Seeking Alpha
Abiomed Stock: Small Premium For Access To ~11% Normalized ROIC
Aug 04, 2022 17:45pm

Abiomed reported robust earnings yesterday with double-digit growth from top-bottom. See why we remain unchanged on our previous rating of buy on ABMD stock.


Source:Seeking Alpha
Abiomed: Q1 Earnings Insights
Aug 04, 2022 14:55pm

Abiomed (NASDAQ: ABMD ) reported its Q1 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Abiomed beat estimated earnings by 17.92%, reporting an EPS of $1.25 versus an … Full story available on Benzinga.com


Source:Benzinga
Abiomed Inc. Q1 Earnings Summary
Aug 04, 2022 11:46am

(RTTNews) - Below are the earnings highlights for Abiomed Inc. (ABMD):


Source:Nasdaq
Abiomed beats top and bottom line; guides FY 2023 topline growth of 13-17%
Aug 04, 2022 11:02am

Abiomed press release (ABMD): Q1 Non-GAAP EPS of $1.25 beats by $0.19.Revenue of $277M (+9.7% Y/Y) beats by $0.54M.Worldwide product revenue of $264 million, an increase…


Source:Seeking Alpha
Abiomed FQ1 2023 Earnings Preview
Aug 03, 2022 15:56pm

Abiomed (ABMD) is scheduled to announce FQ1 earnings results on Thursday, August 4th, before market open.The consensus EPS Estimate is $1.06 (-3.6% Y/Y) and the consensus Revenue…


Source:Seeking Alpha
Artificial Heart Market Share, Size and Demand Report 2022 : Increase in Number of People Suffering from Cardiovascular Diseases : Abbott, AbioMed, MyLVAD
Jul 29, 2022 15:07pm

The Global Artificial Heart Market Size is projected to reach USD 54.28 million by 2028, exhibiting a CAGR of 16.16% during the forecast period. London, UK -- ( SBWIRE ) -- 07/29/2022 -- Artificial hearts are being used to help patients with total heart failure live normal lives past their life expectancy time line, or to help patients survive until their transplant date either by replacing the heart completely or by replacing the ventricles. The device is surgically implanted in the chest in order to help in the functioning of a deteriorating heart. An artificial heart may also be used temporarily and is removed once the heart starts functioning normally. In cases where the damage is severe, the biological heart is completely replaced with the artificial heart. An artificial heart is powered by either compressed air or electricity.The rise in the number of cardiac disorders along with an increase in the geriatric population is anticipated to drive the artificial heart market in the coming years.


Source:SBWire
ABIOMED PT Lowered to $355 at Deutsche Bank
Jul 21, 2022 12:08pm

https://www.investing.com/news/pro/abiomed-pt-lowered-to-355-at-deutsche-bank-432SI-2850675


Source:Investing.com
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
Jul 14, 2022 11:00am

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financials and host conference call to discuss the results for the first quarter of the fiscal year 2023 on August 4, 2022.


Source:Business Wire
US stock market closed mixed, Dow Jones up 0.27%
Jun 30, 2022 03:30am

At the close of the New York Stock Exchange, the Dow Jones was up 0.27%, the S&P 500 was down 0.07% and the NASDAQ Composite was down 0.03%. McDonald''s Corporation was the leading gainer among the components of the Dow Jones in today''s trading, up 4.91 points or 2.02% to close at 247.74. Quotes of Microsoft Corporation rose by 3.78 points (1.47%), closing trading at 260.26. UnitedHealth Group Incorporated rose 7.27 points or 1.43% to close at 515.71. The biggest losers were Caterpillar Inc, which shed 3.96 points or 2.11% to end the session at 183.48. Chevron Corp was up 1.97% or 2.96 points to close at 146.98 while American Express Company was down 1.91% or 2.72 points to close at 139. 47. Among the S&P 500 index components gainers in today''s trading were General Mills Inc, which rose 6.35% to 74.72, ABIOMED Inc, which gained 2.97% to close at 256.49, and shares of Monster Beverage Corp, which rose 2.80% to end the session at 93.35. The biggest losers were shares of Carnival Corporation, which shed 14.13% to close at 8.87.


Source:InstaForex
Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome
Jun 27, 2022 00:00am

The clinical-stage pharma company Acer Therapeutics Inc. (Nasdaq:ACER) has begun screening patients for its Phase 3 DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical study of EDSIVO (celiprolol) to treat COL3A1-positive vascular Ehlers-Danlos syndrome (vEDS). There are presently no FDA-approved drugs available for vEDS, which is associated with a risk of internal bleeding,…


Source:WTWH
Wireless IP adds digital key capability to automotive ICs
Jun 27, 2022 00:00am

CEVA, Inc. announced that its RivieraWaves ultra-wideband (UWB) IP has been extended with the RW-UWB-CCC MAC software package to support the Car Connectivity Consortium (CCC) Digital Key 3.0 specification. Already licensed to one of the largest players in the automotive semiconductor industry for their digital key product line, CEVA’s Digital Key 3.0 compliant UWB IP allows chip vendors…


Source:WTWH
Magnetic sensors optimized for ADAS applications
Jun 27, 2022 00:00am

Allegro MicroSystems, Inc. announced the launch of its A33110 and A33115 magnetic position sensors at the Sensors Converge Conference in San Jose, CA. Designed for advanced driver assistance systems (ADAS) applications that require high levels of accuracy and heterogeneous signal redundancy, Allegro’s newest sensors combine the company’s vertical Hall technology (VHT) with cutting-edge tunneling magnetoresistance (TMR) technology in […]


Source:WTWH
Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome
Jun 27, 2022 00:00am

The clinical-stage pharma company Acer Therapeutics Inc. (Nasdaq:ACER) has begun screening patients for its Phase 3 DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical study of EDSIVO (celiprolol) to treat COL3A1-positive vascular Ehlers-Danlos syndrome (vEDS). There are presently no FDA-approved drugs available for vEDS, which is associated with a risk of internal bleeding,…


Source:WTWH